Takeda’s narcolepsy data reveal why orexin agonists are becoming a neuroscience priority
Find out how Takeda’s oveporexton data could reshape narcolepsy type 1 care as approval, safety and access questions loom.
Pharma & Biotech
Pharma & Biotech
Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window
Find out how Apnimed’s AD109 Phase 3 data could reshape oral treatment for obstructive sleep apnea as FDA review approaches.